To confirm whether NR2F6 protein overexpression is correlated with cervical cancer clinicopathological features, IHC analysis was performed on 189 cervical cancer tissue samples that included FIGO stage IB1 (72 cases, 38.1%), stage IB2 (37 cases, 19.6%), stage IIA1 (54 cases, 28.5%), and stage IIA2 (26 cases, 13.8%) disease. Here, NR2F6 is linked to cervical cancer.